沙库巴曲缬沙坦钠片联合琥珀酸美托洛尔缓释片治疗顽固性心力衰竭的疗效分析  

Analysis of curative effect of sacubitril valsartan sodium tablets combined with metoprolol succinate sustained-release tablets in the treatment of refractory heart failure

作　　者：权泉 QUAN Quan(Department of Cardiology,Jiawang District People's Hospital,Xuzhou 221011,China)

机构地区：[1]徐州市贾汪区人民医院心内科,221011

出　　处：《中国现代药物应用》2025年第6期68-71,共4页Chinese Journal of Modern Drug Application

摘　　要：目的探讨顽固性心力衰竭应用沙库巴曲缬沙坦钠片、琥珀酸美托洛尔缓释片联合治疗的疗效。方法选取102例顽固性心力衰竭患者,按照实施治疗方案的差异分为联合组与对照组,每组51例。对照组在对症治疗基础上予以琥珀酸美托洛尔缓释片治疗,联合组在对照组基础上予以沙库巴曲缬沙坦钠片治疗。对比两组患者临床疗效、心功能指标[左心室舒张末期内径(LVEDD)、每搏输出量(SV)、左心室射血分数(LVEF)、6 min步行试验(6MWT)]、血清学指标[N末端脑利钠肽前体(NT-proBNP)、醛固酮(ALD)]。结果与对照组(76.47%)相比,联合组总有效率(92.16%)更高(P<0.05)。与本组治疗前相比,两组治疗30 d后LVEDD均下降,SV、LVEF、6MWT均上升,且与对照组的(60.15±3.45)mm、(45.42±3.34)ml/min、(52.54±3.29)%、(305.39±20.24)m相比,联合组LVEDD(54.21±3.36)mm更低,SV(50.37±3.61)ml/min、LVEF(63.45±3.63)%、6MWT(328.64±21.47)m更高(P<0.05)。与治疗前相比,两组治疗30 d后NT-proBNP、ALD有所下降,且与对照组的(513.54±44.86)pg/ml、(45.16±5.07)ng/L相比,联合组NT-proBNP(471.28±46.49)pg/ml、ALD(38.59±4.35)ng/L更低(P<0.05)。结论顽固性心力衰竭应用沙库巴曲缬沙坦钠片、琥珀酸美托洛尔缓释片联合治疗的疗效理想,可减轻疾病引起的心功能损伤症状,调节NT-proBNP、ALD等血清学指标。Objective To explore the curative effect of sacubitril valsartan sodium tablets combined with metoprolol succinate sustained-release tablets in the treatment of refractory heart failure. Methods 102 patients with refractory heart failure were selected. According to the difference of treatment plan, they were divided into combination group and control group, with 51 cases in each group. Both groups received symptomatic treatment. On this basis, the control group was treated with metoprolol succinate sustained-release tablets, and the combination group was treated with sacubitril valsartan sodium tablets on the basis of the control group. Both groups were compared in terms of clinical efficacy, cardiac function indexes[ left ventricular end-diastolic diameter (LVEDD), stroke volume (SV), left ventricular ejection fraction (LVEF), 6-min walking test (6MWT)], serological indexes [N-terminal pro-B-type natriuretic peptide (NT-proBNP), aldosterone (ALD)]. Results Compared with the control group (76.47%), the combined group had a higher total effective rate (92.16%) (P<0.05). At 30 d after treatment, LVEDD decreased and SV, LVEF and 6MWT increased in both groups compared with before treatment;compared with (60.15±3.45) mm, (45.42±3.34) ml/min, (52.54±3.29) % and (305.39±20.24) m in the control group the combination group had a lower LVEDD (54.21±3.36) mm, and a higher SV (50.37± 3.61) ml/min, LVEF (63.45±3.63) % and 6MWT (328.64±21.47) m (P<0.05). After treatment, NT-proBNP and ALD were decreased in both groups compared with before treatment;NT-proBNP (471.28±46.49) pg/ml and ALD (38.59±4.35) ng/L in the combination group were lower than (513.54±44.86) pg/ml and (45.16±5.07) ng/L in the control group (P<0.05). Conclusion The combination of sacubitril valsartan sodium tablets and metoprolol succinate sustained-release tablets in the treatment of refractory heart failure has ideal curative effect, which can reduce the symptoms of heart function injury caused by the disease and regulate the serological indexes

关 键 词：顽固性心力衰竭 沙库巴曲缬沙坦钠片 琥珀酸美托洛尔缓释片 心功能 

分 类 号：R541.6[医药卫生—心血管疾病]